A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Status:
RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Phase:
PHASE3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.